1.38

1.43% -0.02

After Hours: 1.33 -0.05 -3.62%

Inmed Pharmaceuticals Inc (INM)

Overview News Price History Financials Discussions Forecast Stock Split

Inmed Pharmaceuticals Inc stock is traded at $1.38, with a volume of 100.71K. It is down -1.43% in the last 24 hours and down -4.17% over the past month. InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.

Previous Close:

$1.40

Open:

$1.38

24h Volume:

100.71K

Relative Volume:

0.11

Market Cap:

$7.58M

Revenue:

$3.25M

Net Income/Loss:

$-8.34M

P/E Ratio:

-0.5358

EPS:

-2.5755

Net Cash Flow:

$-7.71M

1W Performance:

+1.47%

1M Performance:

-4.17%

6M Performance:

+97.45%

1Y Performance:

-36.70%

1-Day Range:

$1.35

$1.40

1-Week Range:

$1.35

$1.46

52-Week Range:

$0.575

$2.4999

Inmed Pharmaceuticals Inc Stock (INM) Company Profile

Name

Inmed Pharmaceuticals Inc

Sector

Healthcare (1067)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

(604) 669-7207

Address

1445-885 WEST GEORGIA ST., VANCOUVER

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

INM's Discussions on Twitter

Compare INM vs TAK, TEVA, HLN, ZTS, VTRS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INM Inmed Pharmaceuticals Inc	1.38	7.58M	3.25M	-8.34M	-7.71M	-2.5755
TAK Takeda Pharmaceutical Co Adr	18.86	60.23B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	39.19	45.71B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.26	40.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	71.05	29.36B	9.51B	2.64B	2.14B	6.0361
VTRS Viatris Inc	17.83	20.48B	14.57B	-296.50M	1.64B	-0.259

Inmed Pharmaceuticals Inc Stock (INM) Latest News

01:28 AM

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET - TMX Newsfile

01:28 AM

Sep 25, 2026

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 - TMX Newsfile

Sep 25, 2026

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules - TMX Newsfile

Sep 25, 2026

Sep 18, 2026

InMed Pharmaceuticals (INM) Faces Nasdaq Equity Shortfall Amid I - GuruFocus

Sep 18, 2026

Form 8K INMED PHARMACEUTICALS INC. For: 18 September By Investing.com - Investing.com Nigeria

Sep 18, 2026

InMed Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Sep 18, 2026

InMed Faces Nasdaq Equity Shortfall but Banks on Mentari Merger to Regain Compliance - TipRanks

Sep 18, 2026

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance - TMX Newsfile

Sep 18, 2026

Sep 16, 2026

10% owner adds to InMed Pharmaceuticals (INM) stake with open-market buys - Stock Titan

Sep 16, 2026

Sep 12, 2026

InMed Reports FY2026 Net Loss Of $12.9 Million As Mentari Merger Advances With $490 Million Financing - Pulse 2.0

Sep 12, 2026

Sep 09, 2026

InMed winds down only revenue-generating business BayMedica - Minichart

Sep 09, 2026

GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 09, 2026

InMed Pharmaceuticals Inc. FY 2026: Revenue $3.18M, EPS ($3.12) — 10-K Summary - TradingView

Sep 09, 2026

[S-4/A] InMed Pharmaceuticals Inc. Amended Business Combination Registration | INM SEC FilingForm S-4/A - Stock Titan

Sep 09, 2026

$490M backs proposed migraine merger at InMed Pharmaceuticals (INM)—what legacy holders keep - Stock Titan

Sep 09, 2026

About $490 million in financing is expected before a proposed merger. InMed still needs shareholder approval. - Stock Titan

Sep 09, 2026

InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update - TMX Newsfile

Sep 09, 2026

Sep 08, 2026

InMed Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Sep 08, 2026

Aug 27, 2026